Patients with breast cancers overexpressing human epidermal growth factor receptor 2 (Her-2) bear an increased risk for developing brain metastases, attributed to longer survival times (1, 2) and inherent genomic modifications (3). This evidence concerns the gene ERBB2 and breast carcinoma.